Study Title
CONNECT1905: Phase 2 Study of Systemic IL-6 Receptor Antagonist ACTEMRA® (tocilizumab) for the treatment of Pediatric Adamantinomatous Craniopharyngioma
Protocol ID
CONNECT1905
Disease (Sub Disease)
Adamantinomatous Craniopharyngioma
Diagnosis Stage
Relapsed/refractory
Location
NSW, QLD, WA
Sponsor
Australian and New Zealand Children's Haematology Oncology Group
Nationwide Children's Hospital
Nationwide Children's Hospital
Collaborators
Children's Hospital Colorado
Links
Trial Status
Open
Sites
Perth Children's Hospital
Sydney Children's Hospital
Queensland Children's Hospital
Sydney Children's Hospital
Queensland Children's Hospital
Study Type
Treatment
Phase
Phase 2
Age Eligibility
1 Year to 25 Years
International registry ID's
NCT05233397
| Study Title | CONNECT1905: Phase 2 Study of Systemic IL-6 Receptor Antagonist ACTEMRA® (tocilizumab) for the treatment of Pediatric Adamantinomatous Craniopharyngioma |
|---|---|
| Protocol ID | CONNECT1905 |
| Disease (Sub Disease) | Adamantinomatous Craniopharyngioma |
| Diagnosis Stage | Relapsed/refractory |
| Location | NSW / QLD / WA |
| Sponsor | Australian and New Zealand Children's Haematology Oncology Group/ Nationwide Children's Hospital |
| Collaborators | Children's Hospital Colorado |
| Links | https://clinicaltrials.gov/ct2/show/NCT05233397 |
| Trial Status | Open |
| Trial Open Date | 19/12/2022 |
| Sites | Perth Children's Hospital/ Sydney Children's Hospital/ Queensland Children's Hospital |
| Study Type | Treatment |
| Phase | Phase 2 |
| Age Eligibility | 1 Year to 25 Years |
| International registry ID's | NCT05233397 |